Results 71 to 80 of about 41,281 (176)

Kinetic Fingerprints as Mechanistic and Clinical Roadmaps Across KIT Activation States

ChemMedChem, Volume 21, Issue 11, 15 June 2026.
Kinetic profiling of 172 compounds across KIT conformations—including D816V—reveals kinetic fingerprints that predict efficacy, selectivity, resistance, and inhibitors’ ability to stabilize key regulatory elements. Far from a secondary metric, binding kinetics provide mechanistic insights beyond affinity, offering a powerful framework for rational drug
Ana Corrionero, Niall Prendiville, Tatiana Cazorla, Maria Baena‐Nuevo, Röhm Sandra, Emilio Camafeita, Stefan Knapp, Patricia Alfonso   +7 more
wiley   +1 more source

Antiviral Use in Mild-to-Moderate SARS-CoV-2 Infections during the Omicron Wave in Geriatric Patients

Viruses
(1) Background: Geriatric patients are at high risk of complications of Coronavirus disease-2019 (COVID-19) and are good candidates for antiviral drugs.
Nadia Exquis, Benjamin Dionisi, Caroline Flora Samer, Victoria Rollason, François Curtin, Dina Zekry, Christophe Graf, Virgnie Prendki, Kuntheavy Ing Lorenzini   +8 more
doaj   +1 more source

Early lipid changes with atazanavir/ritonavir or darunavir/ritonavir

HIV Medicine, 2014
ObjectivesRitonavir‐boosted atazanavir and darunavir are protease inhibitors that are recommended for initial treatment of HIV infection because each has shown better lipid effects and overall tolerability than ritonavir‐boosted lopinavir. The extent to which lipid effects and overall tolerability differ between treatments with atazanavir and darunavir
Martinez, E, Gonzalez-Cordon, A, Ferrer, E, Domingo, P, Negredo, E, Gutierrez, F, Portilla, J, Curran, A, Podzamczer, D, Murillas, J, Bernardino, JI, Santos, I, Carton, JA, Peraire, J, Pich, J, Perez, I, Gatell, JM   +16 more
openaire   +4 more sources

Comparison of Interferon‐Based and Interferon‐Free Treatments on the Prognosis of Hepatocellular Carcinoma After Hepatitis C Virus‐Sustained Virological Response: A Multicenter Study

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT Aim We examine the impact of interferon (IFN)‐based and IFN‐free treatment on the prognosis of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) sustained virological response (SVR). Methods Clinical information was collected on 311 cases of HCC after HCV‐SVR from 16 facilities affiliated with the Kyushu Liver Surgery Study Group ...
Shinji Itoh, Norifumi Iseda, Tomoharu Yoshizumi, Takao Ide, Hirokazu Noshiro, Hisamune Sakai, Toru Hisaka, Masao Nakashima, Hiroaki Nagano, Hirohisa Okabe, Hiromitsu Hayashi, Atsushi Miyoshi, Kenji Kitahara, Yuko Takami, Atsushi Nanashima, Tamotsu Kuroki, Yuichi Endo, Kohji Okamoto, Masatoshi Kajiwara, Masahiko Sakoda, Toru Beppu, Mitsuhisa Takatsuki, Susumu Eguchi   +22 more
wiley   +1 more source

The ‘Health Collapse Spiral’: A 35‐Month Longitudinal Case Study of Physiological Reserve Depletion in a Centenarian Following COVID‐19

Clinical Case Reports, Volume 14, Issue 6, June 2026.
ABSTRACT This 35‐month case report documents irreversible physiological reserve depletion in a centenarian multimorbid man after COVID‐19. Prior to infection, he maintained precarious homeostasis for 17 years despite severe frailty (CFS 7), with stable CKD stage 3a (eGFR 58.3 mL/min/1.73 m2) and albumin 36.2 g/L.
Shan Xu, Wei Zhang, Qiaoxiang Yin, Jie Wei, Yanmin Ma, Wenwen Jia   +5 more
wiley   +1 more source

Clinical Effectiveness of Ritonavir-Boosted Nirmatrelvir—A Literature Review

Advances in Respiratory Medicine
Nirmatrelvir/Ritonavir is an oral treatment for mild to moderate COVID-19 cases with a high risk for a severe course of the disease. For this paper, a comprehensive literature review was performed, leading to a summary of currently available data on ...
Sydney Paltra, Tim O. F. Conrad
doaj   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Targeting Middle East Respiratory Syndrome Coronavirus Spike Fusion Machinery With Antiviral Peptides: In Silico Exploration of the Heptad Repeat 2 Domain

MicrobiologyOpen, Volume 15, Issue 3, June 2026.
Griffithsin, Brevinin‐2, and CCL20 were identified as potent MERS‐CoV fusion inhibitor candidates targeting the HR2 domain through integrated molecular docking, MD simulations, and MM/PBSA analyses. These peptides demonstrated superior binding stability and favorable safety profiles compared to the standard inhibitor, supporting their potential as ...
Nasser Alotaiq, Doni Dermawan, Samir Chtita   +2 more
wiley   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

The Development of an Oral Solution Containing Nirmatrelvir and Ritonavir and Assessment of Its Pharmacokinetics and Stability

Pharmaceutics
Paxlovid®, a co-packaged medication comprised of separate tablets containing two active ingredients, nirmatrelvir (NRV) and ritonavir (RTV), exhibits good effectiveness against coronavirus disease 2019 (COVID-19). However, the size of the NRV/RTV tablets
Lili Wang, Zhuang Ding, Zhengping Wang, Yanna Zhao, Hengqian Wu, Qipeng Wei, Lingfeng Gao, Jun Han   +7 more
doaj   +1 more source